Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 17,43 € (+0,35 %). Medianen er 17,43 € (+0,35 %).

Køb
  4
Behold
  10
Sælg
  0

  • Jim Cramer’s trust buys Kimberly-Clark ahead of Kenvue deal completion

    Jim Cramer’s Charitable Trust bought 50 shares of Kimberly-Clark at about $95.80, bringing its holding to 515 shares and raising the position to roughly 1.24% of the portfolio. The purchase is part of a broader move to deploy a large cash balance into beaten-down non-tech names, with the trust citing the near-term catalyst of the nearly $50 billion Kenvue acquisition expected before year-end. The trust highlights Kimberly-Clark’s 5.3% yield, a roughly 13x forward earnings valuation, and confidence in CEO Mike Hsu to extract more value from Kenvue’s brands via club, e-commerce and international expansion. » Mere på cnbc.com


  • Kimberly-Clark offers asset sales to win EU approval for $40bn Kenvue deal

    Kimberly-Clark is preparing to divest Kenvue assets to address EU antitrust concerns and aims to secure European Commission approval by the September 29 deadline to avoid a lengthier investigation. The company has already faced similar demands in Australia, where conditional approval required selling Carefree and Stayfree. The acquisition would create a consumer-health and personal-care group with about $32 billion in revenue and $7 billion of adjusted EBITDA; Kimberly-Clark cites roughly $1.9 billion in annual cost synergies and $500 million in revenue synergies but expects to invest $2.5 billion to realize cost savings. The scale of any EU divestitures will determine how much of the deal’s expected economic benefits are preserved, while broader remedies or a prolonged review could reduce acquired earnings and delay synergy realization. » Mere på finance.yahoo.com


  • Kenvue pays quarterly dividend of $0.21 on Oct. 2

    Kenvue's board of directors approved a quarterly dividend of $0.21 per common share. The payment will be made on October 2, 2026, to shareholders of record at the close of business on September 21, 2026. » Mere på de.investing.com

I 2026 har Kenvue allerede udloddet 0,73 € i udbytte. Den seneste udlodning fandt sted i oktober.

Virksomhedstal

I det seneste kvartal havde Kenvue en omsætning på 3,47 mia. € og et nettoresultat på 400,49 mio. €
(EUR) juni 2026
YoY
Omsætning 3,47 mia. 6,10 %
Bruttofortjeneste 2,02 mia. 4,81 %
Nettoresultat 400,49 mio. 11,82 %
EBITDA 731,59 mio. 2,50 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
33,59 mia. €
Antal aktier
1,92 mia.
Højeste/laveste i 52 uger
17,99 € - 12,53 €
Udbytteafkast
4,14 %
Udbytte TTM
0,72 €
Beta
0,45
P/E (PE Ratio)
22,49
PEG (PEG Ratio)
1,28
K/I (PB Ratio)
3,56
P/S (PS Ratio)
2,44

Virksomhedsprofil

Kenvue Inc. driver som et forbrugersundhedsselskab på verdensplan. Selskabet opererer gennem tre segmenter: Self Care, Skin Health and Beauty og Essential Health. Segmentet Self Care tilbyder produkter mod hoste, forkølelse og allergi, smertebehandling, mave-tarm-sundhed, rygestop og andre produkter under mærkerne Tylenol, Nicorette og Zyrtec. Segmentet Skin Health and Beauty leverer ansigts- og kropspleje, hårpleje samt solcreme og andre plejeprodukter under mærkerne Neutrogena, Aveeno og OGX. Segmentet Essential Health tilbyder mund- og babypleje, kvindesundhed og sårpleje under mærkerne Listerine, Johnson's, Band-Aid og Stayfree. Selskabet blev stiftet i 2022 og har hovedkontor i Skillman, New Jersey. Kenvue Inc. er et datterselskab af Johnson & Johnson.

Navn
Kenvue
CEO
Kirk L. Perry
Hjemsted Summit, nj
USA
Websted
Sektor
Dagligvarer
Branche
Dagligvarer: distribution og detailhandel
Børsnotering
04.05.2023
Medarbejdere 21.890

Tickersymboler

Børs Symbol
NYSE
KVUE
Frankfurt
J4D.F
Düsseldorf
J4D.DU
Hamburg
J4D.HM
München
J4D.MU
🍪

Parqet  bruger cookies. Læs mere